Skip to main content
Clinical Trials/NCT07487454
NCT07487454Not yet recruitingNot Applicable

Sham-Controlled Rapid-Acting Neuromodulation for Depression

University of California, Davis1 site in 1 country264 target enrollmentStarted: December 1, 2026Last updated:
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
264
Locations
1
Primary Endpoint
Montgomery-Åsberg Depression Rating Scale (MADRS)

Study Overview

Brief Summary

The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults.

The main questions it aims to answer are:

  • Does accelerated iTBS reduce depressive symptoms compared to sham (placebo) stimulation?
  • Are there measurable brain, biological, and digitally measured emotion changes associated with treatment response?

Participants will:

  • Be randomly assigned to receive either active iTBS or sham stimulation
  • Receive 10 stimulation sessions per day for 5 consecutive days (total of 50 sessions)
  • Complete MRI brain scans and EEG recordings before and after treatment
  • Provide blood and saliva samples to measure biological markers
  • Complete depression rating scales and questionnaires at baseline, during treatment, and at follow-up visits
  • Use a secure mobile app to record brief facial and vocal samples during the 5-day treatment and at follow-up visits
  • Return for follow-up visits at 1 week and at 1, 3, 6, and 12 months after treatment

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • English speaking
  • Able to provide informed consent
  • 18-65 years old
  • Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI)

Exclusion Criteria

  • Unable to consent (due to medical condition, acute psychosis, substance use, etc)
  • Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion
  • Active substance use or severe substance use that in the opinion of the PI would interfere with study participation
  • Untreated, active psychosis
  • Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study
  • Contraindications to receiving TMS and/or MRI as determined by screening questionnaires
  • Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies.

Arms & Interventions

Active iTBS

Experimental

The active iTBS group will receive 10 hourly intermittent theta burst stimulation (iTBS) sessions per day for 5 consecutive days.

Intervention: intermittent theta burst stimulation (Device)

Sham iTBS

Sham Comparator

Participants assigned to the sham group will receive 10 hourly sham sessions per day for 5 consecutive days.

Intervention: Sham (No Treatment) (Device)

Outcomes

Primary Outcomes

Montgomery-Åsberg Depression Rating Scale (MADRS)

Time Frame: Baseline through study completion, 1 year

Change in depressive symptoms (MADRS scores)

Secondary Outcomes

  • Change in large-scale brain network connectivity measured by fMRI(Baseline through study completion, 1 year)
  • Change in electroencephalography (EEG) spectral power(Baseline through study completion, 1 year)
  • Change in facial and vocal affective expression(Baseline through study completion, 1 year)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Sham-Controlled Rapid-Acting... | Clinical Trial